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Following the first reports in 1954 of the 
beneficial effects of chloroquine in cases of 
lupus erythematosus1, this drug and its 
numerous derivatives have been used 
extensively in the treatment of systemic 
and discoid lupus erythematosus and 
rheumatoid arthritis. The small dosage of 
chloroquine used in the prophylaxis of 
malaria is comparativley free from any 
serious side effects; higher dosage 
administered over a prolonged period of 
time for chronic connective tissue disorders 
gives rise to concern and requires careful 
monitoring. 
Chloroquine is rapidly absorbed from the 
digestive tract but elimination is slow and 
pronounced accumulation of the drug in 
cellular tissues occurs. The highest 
concentration is reached in melanin 
containing tissues such as the iris, choroid 
and the retinal pigment epithelium2• The 
incidence of corneal changes varies from 
30% - 70%3. The pattern of corneal deposits 
varies from diffuse punctate opacities 
which may aggregate into isolated 
maculae, to radial and whirling lines that 
converge and coalesce in a zone just 
beneath the centre of the cornea. They are 
best visualised on slit-lamp examination. 
They give rise to little subjective symptoms 
apart from photophobia or observation of 
haloes around lights. These minor 
symptoms tend to disappear on dose 
reduction since corneal changes are largely 
reversible and the visual acuity remains 
unaffected. Detection of these changes 
should alert the physician to the possibility 
of the onset of retinal changes at a later 
stage. Corneal sensation is reduced in 50% 
of patients receiving antimalarials with no 
definite relationship to the corneal 
opacities ' ; this may account for fewer 
patients requiring artificial tear substitutes. 
A reduction in the amplitude of 
accommodation is not uncommon - most 
patients complain of difficulty focusing 
from near objects to far or vice-versa. 
Tiny white opacities beneath the posterior 
capsule of the lens have been observed in 
20% - 40% of patients on chloroquine but not 
on hydroxychloroquine5• 
The development of retinopathy is however 
the most serious and potentially blinding 
complication of long term antimalarial 
therapy. Following the first suspected case 
reported by Cambiaggi in 19576, retinal 
toxicity was confirmed in a later study.7. 
The usual presenting symptoms of 
chloroquine retinopathy are difficulty in 
reading with inability to pick out words or 
single letters which may be missing, blurred 
vision and absent areas in the central and 
peripheral visual fields. 
The earliest fundus appearances show fine 
pigmented stippling at the macula of both 
eyes, which are often difficult to distinguish 
from other causes of pigmentation. If the 
drug is discontinued at this premaculo­
pathy stage, the macula may return to 
normal. 
The classic syndrome shows a bilateral 
symmetrical oval pigmentation surrounded 
by a clear zone of depigmentation which is 
encircled by a further ring of pigment; the 
whole pattern resembles a dough-nut or the 
bull's eye of a target. In later stages the disc 
turns pale, the arterioles show generalised 
attenuation and segmental constriction. 
'Bone corpuscle' type of peripheral 
pigmentation is a late feature. The 
diagnosis is confirmed by plotting 
characteristic pericentral or paracentral 
scotomas and by fluorescein angiography 
which shows transmission defects of the 
retinal pigment epithelium with the typical 
bull's eye lesion. These fundu~ changes may 
progress after cessation oftreatmentB, or the 
onset delayed as late as seven years after 
withdrawal of the drug. 9 Histological 
examination shows destruction of rod and 
cone elements, with accumulation of 
pigmented cells in the outer nuclear and 
outer plexiform layers. Phototoxicity may 
be relevant since retinopahty is retarded if 
experimental rats are kept in the dark. 
Albino rats also develop the condition, 
casting doubt on the importance of the 
pigment epithelium. 
How can this condition be prevented? Any 
patient being considered for long term 
antimalarials should have regular 
ophthalmological supervision, with an 
initial baseline assessment prior to 
commencing therapy in order to record any 
existing abnormalities, preferably recorded 
by colour fundus photography. The 
selection of drug is important since 
hydroxychloroquine (Plaquenil) is less toxic 
than chloroquine. Toxicity is related to 
exceeding the maximum allowable daily 
dose (400 mg. hydroxychloroquine or 250 
mg. chloroquine) rather than the total dose 
administered or duration of therapy10. Safe 
and practical dosage limits are 4 mg/ kg. 
body weight/day for chloroquine and 6 
mglkg.lday for hydroxychloroquine11 • The 
risk of retinopathy increases significantly 
above a total dose of 100 gm (representing 
one year's therapy). A simple and 
inexpensive method of early detection is the 
use of an Amsler Grid Chart on which the 
patient may observe any early scotoma, 
which correlates well with more 
sophisticated perimetry l 2 . The electroretin­
ogram and electrooculogram are normal 
when only the macula is affected; both 
responses drop progressively with more 
diffuse damage. Changes in thresholds to 
red and white lights can be detected by the 
Friedman visual field analyserl 3 . Changes 
in visual evoked potentials after photostress 
may precede clinically detectable macular 
change1' . 
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